Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in t…
The US trade magazine "Healthcare Tech Outlook" recently named ibidi GmbH one of the ten best European manufacturers of…
Das Clustermanagement Gesundheitswirtschaft Berlin-Brandenburg – HealthCapital hat eine Bestandsaufnahme zum Digital…
Krebsfrei statt dreimonatiger Lebenserwartung – Wissenschaftler und Wissenschaftlerinnen von ASC Oncology haben mit Hilf…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Die Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugaten (ADCs),…
A new EMBL study reveals how the cancer-promoting MAGE family of proteins bind to their targets, aiding the development…
Krebs-Therapien mit so genannten „Immuncheckpoint-Inhibitoren“ (ICI) sind inzwischen weit verbreitet, doch ihre Langzeit…